Here’s what you should know:
1. QuintilesIMS surveyed 202 gastroenterologists.
2. Approximately 53 percent of gastroenterologists selected IBGard as their preferred treatment for the third consecutive year. The closest competitor earned 14 percent of physician recommendations.
3. IM HealthSciences estimates 10,000 physicians use IBgard for their patients.
IM HealthScience’s Chief Medical Advisor Michael Epstein, MD, said in a release, “The widespread adoption of IBgard among gastroenterologists over the years reflects their real-world experience in receiving positive feedback from their patients with IBS. Real-world patient feedback coupled with compelling clinical data is why IBgard has become a popular mainstay in the management of IBS, a difficult-to-treat condition.”
More articles on gastroenterology:
GI leader to know: Dr. Ravi Mallavarapu of Cedar Valley Gastroenterology
The VA has a high HCV treatment rate — 7 insights into why they’re so successful
5 latest findings on gut microbiome & human development
